Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Switching From Interferon Beta-1a to Alemtuzumab Improves MS Outcomes

Key clinical point: Clinical and imaging outcomes improve among patients with MS who switch from interferon beta-1a to alemtuzumab.

Major finding: The rate of freedom from relapse ranged from 83% to 90%, and disability scores were stable for 51% of patients.

Study details: An examination of data for 117 patients with MS who participated in extensions of the CARE-MS II trial.

Disclosures: Sanofi and Bayer HealthCare Pharmaceuticals supported this study. Dr. Ionete received research support from Biogen, Roche, and Sanofi. She reported receiving compensation for advisory board participation from Sanofi.